Connecting people with clinical trials is complicated — even if people identify a promising match, there’s a slew of potentially thorny factors, including geographic incompatibility, and financial and time considerations. Simply finding an appropriate trial can present an enormous hurdle. In a recent online survey of more than 2,000 adults, 71% of patients with chronic
You don't have permission to access "http://www.medpagetoday.com/psychiatry/generalpsychiatry/121143" on this server. Reference #18.670ed217.1778094141.1bb8cbd6 https://errors.edgesuite.net/18.670ed217.1778094141.1bb8cbd6
The trial of a woman who allegedly killed her partner is set to start. The Centre for Applied Legal Studies is defending a mother of two who is accused of killing her allegedly abusive partner.The trial against the woman begins in the Palm Ridge Magistrate's Court on Wednesday.The woman was denied bail and has been away…
A man and woman are on trial for allegedly severely abusing their minor children.One child, a boy, died and the other suffered several injuries.Advocacy group WMACA is calling for the amendment of Section 110 of the Children's Act to make it compulsory for people to report child abuse they are aware of.A man and woman…
Robert F. Kennedy Jr. has rightly made “radical transparency” the motto of his Department of Health and Human Services. HHS even has a page by that name. I think it is a good motto, and I want to help Secretary Kennedy and Acting FDA Commissioner Kyle Diamantas deliver on it in food safety, with two citizen petitions
Published: October 30, 2026, 10:16 pm Several reports of children choking have led to an FDA warning against Once Upon A Time snacks. The warning covers all flavors, quantities, lots and dates of Once Upon A Farm Tractor Wheels Organic, Toddler Soft-Baked Bars. The FDA has received several reports that describe infants ages 1.5 to
The FDA has cleared the interleukin (IL)-23 inhibitor tildrakizumab (Ilumya) for the treatment of active psoriatic arthritis (PsA) in adults. Sun Pharma announced the approval on October 30. “As an IL-23 inhibitor administered exclusively by a healthcare provider, Ilumya is now an option for adults with active psoriatic arthritis who are unable to self-administer treatment